Stakeholders’ Voices of Lung Cancer Screening in Hong Kong: Study Protocol for a Mixed Methods Study
Abstract
:1. Introduction
2. Methods and Analysis
2.1. Research Questions
2.2. Design
2.3. Theoretical Framework
2.4. Sample
2.5. Setting and Recruitment Procedures
2.6. Instruments
2.7. Data Analysis
2.8. Patient and Public Involvement
3. Discussion
3.1. Strengths
3.2. Limitations
3.3. Dissemination
Funding
Institutional Review Board Statement
Data Availability Statement
Conflicts of Interest
References
- World Health Organization. Lung Cancer. 2023. Available online: https://www.who.int/news-room/fact-sheets/detail/lung-cancer (accessed on 1 October 2023).
- Lee, P.N.; Forey, B.A.; Hong Kong Cancer Registry, Hospital Authority. Lung Cancer in 2014. 2014. Available online: http://www3.ha.org.hk/cancereg/pdf/factsheet/2014/lung_2014.pdf (accessed on 1 October 2023).
- Department of Health and Census and Statistics Department, HKSAR. Mortality Statistics, 2020. 2020. Available online: https://www.chp.gov.hk/en/healthtopics/content/25/49.html#:~:text=Lung%20cancer%20was%20the%20first,26.7%25%20of%20all%20cancer%20deaths (accessed on 1 October 2023).
- International Agency for Research on Cancer, World Health Organization. List of Classifications by Cancer Sites with Sufficient or Limited Evidence in Humans, Volumes 1 to 117*. Last update: 24 October 2016. Available online: http://monographs.iarc.fr/ENG/Classification/Table4.pdf (accessed on 1 October 2023).
- Lee, P.N.; A Forey, B.; Coombs, K.J. Systematic review with meta-analysis of the epidemiological evidence in the 1900s relating smoking to lung cancer. BMC Cancer 2012, 12, 385. [Google Scholar] [CrossRef] [PubMed]
- Eriksen, M.; Mackay, J.; Schluger, N.; Gomeshtapeh, F.I.; Drope, J. The Tobacco Atlas, 5th ed.; American Cancer Society: Atlanta, GA, USA, 2015; Available online: http://www.tobaccoatlas.org (accessed on 1 October 2023).
- World Cancer Research Fund; American Institute for Cancer Research. Food, Nutrition, Physical Activity and the Prevention of Cancer: A Global Perspective; American Institute for Cancer Research: Washington, DC, USA, 2021; Available online: http://www.wcrf.org/sites/default/files/english.pdf (accessed on 1 October 2023).
- Outdoor Air Pollution, IARC Working Group on the Evaluation of Carcinogenic Risk to Humans. Lyon, France: International Agency for Research on Cancer, World Health Organization. 2015; Volume 109. Available online: http://monographs.iarc.fr/ENG/Monographs/vol109/mono109.pdf (accessed on 1 October 2023).
- Pirie, K.; Peto, R.; Reeves, G.K.; Green, J.; Beral, V. The 21st century hazards of smoking and benefits of stopping: A prospective study of one million women in the UK. Lancet 2013, 381, 133–141. [Google Scholar] [CrossRef] [PubMed]
- National Lung Screening Trial Research Team; Aberle, D.R.; Adams, A.M.; Berg, C.D.; Black, W.C.; Clapp, J.D.; Fagerstrom, R.M.; Gareen, I.F.; Gatsonis, C.; Marcus, P.M. Reduced lung-cancer mortality with low-dose computed tomographic screening. N. Engl. J. Med. 2011, 365, 395–409. [Google Scholar] [CrossRef] [PubMed]
- Miller, K.D.; Nogueira, L.; Mariotto, A.B.; Rowland, J.H.; Yabroff, K.R.; Alfano, C.M.; Jemal, A.; Kramer, J.L.; Siegel, R.L. Cancer treatment and survivorship statistics, 2019. CA Cancer J. Clin. 2019, 69, 363–385. [Google Scholar] [CrossRef] [PubMed]
- Centre for Health Protection. Cancer Expert Working Group on Cancer Prevention and Screening Recommendations on Prevention and Screening for Lung Cancer for Health Professionals. 2018. Available online: https://www.chp.gov.hk/files/pdf/lung_cancer_professional_hp.pdf (accessed on 1 October 2023).
- U.S. Preventive Services Task Force. Lung Cancer: Screening. 2021. Available online: https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/lung-cancer-Screening (accessed on 1 October 2023).
- Ji, G.; Bao, T.; Li, Z.; Tang, H.; Liu, D.; Yang, P.; Li, W.; Huang, Y. Current lung cancer screening guidelines may miss high-risk population: A real-world study. BMC Cancer 2021, 21, 50. [Google Scholar] [CrossRef] [PubMed]
- Canadian Task Force on Preventive Health Care. Lung Cancer. 2016. Available online: https://canadiantaskforce.ca/guidelines/published-guidelines/lung-cancer/ (accessed on 1 October 2023).
- Oudkerk, M.; Devaraj, A.; Vliegenthart, R.; Henzler, T.; Prosch, H.; Heussel, C.P.; Bastarrika, G.; Sverzellati, N.; Mascalchi, M.; Delorme, S.; et al. European position statement on lung cancer screening. Lancet Oncol. 2017, 18, e754–e766. [Google Scholar] [CrossRef] [PubMed]
- Japan Radiologic Society. The Japanese Imaging Guideline. 2013. Available online: http://www.radiology.jp/english/guideline.html (accessed on 1 October 2023).
- So, W.K.; Law, B.M.; Choi, K.C.; Chan, D.N.; Chan, C.W. A mixed-method study examining cancer screening uptake among south asian ethnic minorities in Hong Kong. Asia-Pac. J. Oncol. Nurs. 2019, 7, 12–17. [Google Scholar] [CrossRef] [PubMed]
- Chan, D.N.S.; So, W.K.W. Influential barriers perceived by South Asians in Hong Kong to undergoing cervical cancer screening. Eur. J. Cancer Care 2022, 31, e13556. [Google Scholar] [CrossRef] [PubMed]
- Wong, M.C.S.; Ching, J.Y.L.; Hirai, H.H.; Lam, T.Y.T.; Griffiths, S.M.; Chan, F.K.L.; Sung, J.J.Y. Perceived obstacles of colorectal cancer screening and their associated factors among 10,078 Chinese participants. PLoS ONE 2013, 8, e70209. [Google Scholar] [CrossRef] [PubMed]
- Lin, Y.-A.; Carter-Harris, L.; Yang, J.-N.; Lin, X.J.; Huang, F.F. Adaptation and validation of the Chinese version of the lung cancer screening health belief scales. BMC Public Health 2022, 22, 620. [Google Scholar] [CrossRef] [PubMed]
- Glanz, K.; Rimer, B.; Viswanath, K. Health Behavior and Health Education: Theory, Research, and Practice; Jossey-Bass: San Francisco, CA, USA, 2008; Available online: https://www.med.upenn.edu/hbhe4/ (accessed on 1 October 2023).
- Janz, N.K.; Becker, M.H. The Health Belief Model: A Decade Later. Health Educ. Behav. 1984, 11, 1–47. [Google Scholar] [CrossRef] [PubMed]
- Arifin, W. Sample Size Calculator. 2022. Available online: https://wnarifin.github.io/ssc_web.html (accessed on 1 October 2023).
- MacCallum, R.; Widaman, K.; Preacher, K.; Hong, S. Sample Size in Factor Analysis: The Role of Model Error. Multivariate Behavioral Research. Multivariate Behavior Research. 2001. Available online: https://pubmed.ncbi.nlm.nih.gov/26822184/ (accessed on 1 October 2023).
- Carter-Harris, L.P.; Slaven, J.E.I.M.; Monohan, P.; Rawl, S.M. Development and psychometric evaluation of the Lung Cancer Screening Health Belief Scales. Cancer Nurs. 2017, 40, 237–244. [Google Scholar] [CrossRef] [PubMed]
- Brislin, R.W. The wording and translation of research instruments. In Field Methods in Cross-Cultural Research; Loner, W.J., Berry, J.W., Eds.; Beverly Hills: Sage, CA, USA, 1986; pp. 137–164. [Google Scholar]
- Lowenstein, L.M.; Richards, V.F.; Leal, V.B.; Housten, A.J.; Bevers, T.B.; Cantor, S.B.; Cinciripini, P.M.; Cofta-Woerpel, L.M.; Escoto, K.H.; Godoy, M.C.; et al. A brief measure of Smokers’ knowledge of lung cancer screening with low dose computed tomography. Prev. Med. Rep. 2016, 4, 351–356. [Google Scholar] [CrossRef] [PubMed]
- Cataldo, J.K.; Slaughter, R.; Jahan, T.M.; Pongquan, V.L.; Hwang, W.J. Measuring stigma in people with lung cancer: Psychometric testing of the cataldo lung cancer stigma scale. Oncol. Nurs. Forum 2011, 38, E46–E54. [Google Scholar] [CrossRef] [PubMed]
- Spitzer, R.L.; Kroenke, K.; Williams, J.B.W.; Löwe, B. A brief measure for assessing generalized anxiety disorder: The GAD-7. Arch. Intern. Med. 2006, 166, 1092–1097. [Google Scholar] [CrossRef] [PubMed]
- Kroenke, K.; Spitzer, R.L.; Williams, J.B. The PHQ-9: Validity of a brief depression severity measure. J. Gen. Intern. Med. 2001, 16, 606–613. [Google Scholar] [CrossRef] [PubMed]
- Dugan, E.; Trachtenberg, F.; A Hall, M. Development of abbreviated measures to assess patient trust in a physician, a health insurer, and the medical profession. BMC Health Serv. Res. 2005, 5, 64. [Google Scholar] [CrossRef] [PubMed]
- Hu, L.T.; Bentler, P.M. Cutoff criteria for fit indexes in covariance structure analysis: Conventional criteria versus new alternatives. Struct. Equ. Model. Multidiscip. J. 1999, 6, 1–55. [Google Scholar] [CrossRef]
Country/Area | Guideline |
---|---|
United States | Adults aged 50 to 80 years old who have a 20 pack-year smoking history and currently smoke or have quit within the past 15 years should screen lung cancer annually with LDCT. Screening should be discontinued once a person has not smoked for 15 years or develops a health problem that substantially limits life expectancy or the ability or willingness to have curative lung surgery. |
China | Chinese individuals aged 50 to 75 years old, with at least one of the following risk factors, should screen lung cancer annually with LDCT: (1) at least 20 pack-years of cigarette smoking history, including currently smoking or giving up smoking for less than 15 years; (2) passive smoking; (3) a history of occupational exposure, including asbestos, beryllium, uranium, radon, etc.; (4) a history of cancer or a family history of lung cancer; and (5) a history of chronic obstructive pulmonary disease or diffuse pulmonary fibrosis. |
Hong Kong | For the general population or high-risk populations, routine screening for lung cancer with a chest X-ray or sputum cytology is not recommended, and there is insufficient evidence to recommend for or against lung cancer screening by LDCT in asymptomatic persons or for mass screening. |
Canada | For adults aged 55 to 74 years with at least a 30 pack-year* smoking history who currently smoke or quit less than 15 years ago, annual screening with LDCT up to three consecutive times is recommended. Screening should only be carried out in healthcare settings with expertise in early diagnosis and treatment of lung cancer (weak recommendation with low quality evidence) [15]. |
European Union | A validated risk stratification approach should be used to select people who should be screened for future lung cancer low-dose CT programs [16]. |
Japan | For people who are aged 50 or over with a Brinkman index ≥600 (i.e., ≥30 pack-years of smoking), LDCT screening may be considered for population-based screening [17]. |
Thank you for your interest in this study. I am going to ask you some questions about your knowledge of lung cancer screening, attitude toward lung cancer screening with low dose computed tomography and readiness to implement lung cancer screening. Your responses to the questions will be recorded by the digital recorders. Our conversation is confidential and no information about your identity will be shared. |
Knowledge about lung cancer screening |
1. How much do you know about lung cancer screening? |
2. Who do you think should screen lung cancer annually? |
3. What method do you think should be used for screening lung cancer? |
4. What benefits and risks do you think may be associated with lung cancer screening? |
Attitude toward lung cancer screening with low dose computed tomography |
1. What is your attitude toward lung cancer screening with low dose computed tomography? |
2. Did you recommend your patients who have a high risk for lung cancer to screening for lung cancer? What are the reasons for your recommendation/not having such recommendation? |
3. Do you support screening lung cancer with low dose computed tomography among people who have high risk for lung cancer? Why? |
4. Do you think that both public and private insurances should cover the cost of lung cancer screening in high-risk population? Why? |
Readiness to implement lung cancer screening |
1. Do you think you are ready to recommend lung cancer screening with low dose computed tomography to your patients who have high risk of lung cancer? |
(Prompt): If yes, what efforts have you put into that enables you to do so? If not, what help do you think is needed for you to do so? |
2. Do you think a guideline about screening for lung cancer is needed to be enacted in Hong Kong? |
(Prompt): If yes, who do you think should make efforts to enable that guideline to be enacted? If no, what are the reasons? When do you think is a good time to enact that guideline? |
3. What works need to be done before that guideline can be enacted? |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2024 by the author. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Lei, F. Stakeholders’ Voices of Lung Cancer Screening in Hong Kong: Study Protocol for a Mixed Methods Study. Healthcare 2024, 12, 142. https://doi.org/10.3390/healthcare12020142
Lei F. Stakeholders’ Voices of Lung Cancer Screening in Hong Kong: Study Protocol for a Mixed Methods Study. Healthcare. 2024; 12(2):142. https://doi.org/10.3390/healthcare12020142
Chicago/Turabian StyleLei, Fang. 2024. "Stakeholders’ Voices of Lung Cancer Screening in Hong Kong: Study Protocol for a Mixed Methods Study" Healthcare 12, no. 2: 142. https://doi.org/10.3390/healthcare12020142
APA StyleLei, F. (2024). Stakeholders’ Voices of Lung Cancer Screening in Hong Kong: Study Protocol for a Mixed Methods Study. Healthcare, 12(2), 142. https://doi.org/10.3390/healthcare12020142